Briefing: CDC Stops Testing for Rabies, Pox Viruses
Strategic angle: When medical misinformation wins, testing an antidepressant for meth use, and other health news.
Editorial Staff Apr 2
Health
Latest Health stories from Life.
Briefing: STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Strategic angle: How 'Takeover Tuesday' saved biotech's first quarter.
Editorial Staff Apr 2
Briefing: Beyond detection: In the age of clinical AI, what counts as an FDA ‘breakthrough’ medical device?
Strategic angle: An analysis of AI-powered devices that received FDA's 'breakthrough' label shows a preference for big-picture, multi-problem solutions.
Editorial Staff Apr 2
Briefing: Opinion: Medical misinformation wins when patients can’t see their doctors
Strategic angle: Desperate patients, unable to get timely doctors’ appointments, seek help wherever they can find it.
Editorial Staff Apr 2
Briefing: Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Strategic angle: Prevention is normally relegated to the periphery of national medical conferences. Not anymore.
Editorial Staff Apr 2
Briefing: STAT reporter goes up against radiologists to spot deepfake X-rays
Strategic angle: A STAT reporter challenges radiologists in identifying deepfake X-rays in this week's STATus Report.
Editorial Staff Apr 2
Briefing: Trump Administration Prepares 100% Tariffs on Some Imported Drugs
Strategic angle: The White House is readying a 100% tax on some imported medicines, a draft order shows.
Editorial Staff Apr 2
Briefing: Makary Marks One Year at FDA with Focus on Achievements
Strategic angle: The FDA commissioner praised staff and listed his accomplishments in a speech to workers.
Editorial Staff Apr 1
Briefing: Large AI Scribe Study Finds Modest Time Savings for Doctors
Strategic angle: A new study reveals that AI scribes saved doctors approximately 16 minutes during an eight-hour shift across five academic medical centers.
Editorial Staff Apr 1
Briefing: Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest
Strategic angle: A new review reveals the FDA's shortcomings in disclosing financial conflicts of interest among advisory committee members.
Editorial Staff Apr 1
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk
Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill.
Editorial Staff Apr 1
Briefing: Policy Tracker: Exceptions to State Abortion Bans and Early Gestational Limits
Strategic angle: This policy tracker documents exceptions in each state’s most restrictive gestational limit or total ban.
Editorial Staff Apr 1
Briefing: Insilico Medicine CEO on Best Practices for AI in Drug Development
Strategic angle: Insights from Alex Zhavoronkov on becoming a productive biotech AI company.
Editorial Staff Apr 1
Briefing: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Strategic angle: A delayed FDA decision for Orca Bio, new questions about pharma-telehealth tie-ups, and more
Editorial Staff Apr 1
Briefing: FDA Moves Toward Allowing Injectable Peptide Compounding
Strategic angle: The FDA is reconsidering its stance on compounding pharmacies, potentially allowing the production of injectable peptides previously banned due to safety concerns.
Editorial Staff Apr 1
Briefing: KFF Health Tracking Poll: The Public’s View of Immigration Enforcement Activities in Health Care Settings
Strategic angle: A majority of the public expresses concern over immigration enforcement in hospitals amid policy changes.
Editorial Staff Apr 1
Briefing: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Strategic angle: A new study explores whether incorporating psychotherapy with ketamine treatment enhances its effectiveness.
Editorial Staff Apr 1
Briefing: NIH Director's Invocation of Vannevar Bush's Legacy Sparks Pushback
Strategic angle: Jay Bhattacharya's claim linking Trump administration policies to Vannevar Bush's vision has ignited controversy.
Editorial Staff Apr 1
Briefing: Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression
Strategic angle: “Rigorously derived evidence for the medical efficacy of marijuana is thin,” writes Kevin Sabet.
Editorial Staff Apr 1
Briefing: Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene
Strategic angle: Medicare is restricting care for 1 million Americans based on a faulty assumption.
Editorial Staff Apr 1